Global Cardiac Biomarkers Market Size Study & Forecast, by Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), by Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others), by End use (Laboratory Testing, Poi

Global Cardiac Biomarkers Market Size Study & Forecast, by Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), by Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, Others), by End use (Laboratory Testing, Point of Care Testing), and Regional Analysis, 2023-2030

Global Cardiac Biomarkers Market is valued at approximately USD 16.05 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 14.6% over the forecast period 2023-2030. Cardiac biomarkers are molecules released into the bloodstream in response to heart damage or stress. The assessment of these biomarkers is a valuable tool in the diagnosis of conditions such as Acute Coronary Syndrome (ACS) and cardiac ischemia, both of which are characterized by inadequate blood supply to the heart. Additionally, tests for cardiac biomarkers serve to evaluate an individual's risk of developing these conditions and are instrumental in monitoring and managing individuals with suspected ACS and cardiac ischemia. The increasing demand for rapid diagnostic tests, the rise in initiatives to promote heart health, and regular screening for CVDs, along with the increasing aging population are the key factors that are fueling the demand for cardiac biomarkers across the globe.

The global prevalence of CVDs, including heart attacks and heart failure, is increasing, driving the demand for cardiac biomarker tests to aid in diagnosis and monitoring. According to the World Health Organization (WHO), it was estimated that Cardiovascular Diseases (CVDs) are recorded as the leading cause of death around the world, which takes an estimated 17.9 million lives annually. Additionally, heart attacks and strokes account for 85% of these cardiovascular disease deaths. In addition, according to an article that was published in the Cureus Journal of Medical Science in July 2020, Ischemic Heart Disease (IHD) is a significant cause of death globally. Around 126 million people worldwide (1,655 per 100,000), or roughly 1.72% of the world's population, suffer from ischemic heart disease. It is anticipated that more than 1,845 cases of ischemic heart disease per 100,000 people worldwide by 2030. Consequentially, the rise in incidences of CVDs are propelling the growth of the Cardiac Biomarkers Market during the estimated period. Moreover, the surge in demand for Point-of-Care (POC) cardiac diagnostics, as well as the growing demand for rapid diagnostic tests present various lucrative opportunities over the forecast years. However, the complexities associated with cardiac biomarker tests and the stringent regulatory frameworks are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Cardiac Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the presence of a well-established healthcare system and the widespread adoption of cardiac biomarkers as a diagnostic and predictive tool for various medical conditions. The increasing elderly population, often in need of biomarker testing to detect conditions such as acute myocardial infarction, is a driving force behind the demand for these testing products. Furthermore, the presence of key industry players such as Quidel Corporation and Danaher Corporation in the region is an additional contributing factor to the market's growth. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The increasing accessibility to advanced cardiac tests, ongoing modernization efforts, and rising disposable incomes are significant contributing factors. Moreover, the escalating prevalence of cardiovascular diseases (CVDs) in this region has led to a heightened need for enhanced diagnostic tools. Government funding for targeted disease research and increased healthcare spending are also playing crucial roles. In comparison to other developing nations, India stands out with a higher incidence of CVDs. This substantial disease burden is anticipated to fuel the demand for cardiac biomarker diagnostics, as they play a pivotal role in enabling the diagnosis, assessment, and treatment of CVDs.

Major market players included in this report are:
Abbott
Quidel Corporation
Siemens Healthcare GmbH
F. Hoffmann-La Roche Ltd.
Danaher Corporation
BIOMÉRIEUX
Bio-Rad Laboratories, Inc.
Randox Laboratories Ltd.
Creative Diagnostics
Life Diagnostics, Inc.

Recent Developments in the Market:
 In November 2022, OMRON Healthcare and CardioSignal announced the company's partnership agreement to develop early cardiovascular disease detection technology for cardiac health management. This partnership presents digital cardiac biomarkers that potentially save lives.
 In April 2021, Roche announced a series of five new planned uses for two important cardiac biomarkers (cTnT-hs) using the Elecsys technology, which has the very sensitive cardiac troponin T and NT-proBNP. This helps in improving risk detection and diagnosis and enables the company to make additional revenues from its current product line.

Global Cardiac Biomarkers Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type, Application, End use, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:
Troponin
CK-MB
Myoglobin
BNP and NT-proBNP
Others

By Application:
Acute Coronary Syndrome
Myocardial Infarction
Congestive Heart Failure
Others

By End use:
Laboratory Testing
Point of Care Testing

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa



Companies Mentioned
Abbott
Quidel Corporation
Siemens Healthcare GmbH
F. Hoffmann-La Roche Ltd.
Danaher Corporation
BIOMÉRIEUX
Bio-Rad Laboratories, Inc.
Randox Laboratories Ltd.
Creative Diagnostics
Life Diagnostics, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.